MIRA INFORM REPORT

 

 

Report No. :

318687

Report Date :

27.04.2015

 

IDENTIFICATION DETAILS

 

Name :

ZOLL MEDICAL CORPORATION

 

 

Registered Office :

269 Mill Road, Chelmsford, MA 01824

 

 

Country :

United States

 

 

Date of Incorporation :

04.09.1980

 

 

Legal Form :

Corporation – Profit  

 

 

Line of Business :

  • Develops, manufactures, and markets resuscitation devices, related data management and software solutions, and temperature management technology worldwide.
  • Subject provides technologies that help clinicians, EMS and fire professionals, and lay rescuers in treating victims needing resuscitation and critical care. It offers lifevest wearable defibrillators for various indications comprising heart attack, before or after bypass surgery, or stent placement; patients with cardiomyopathy or congestive heart failures; and patients awaiting an implantable defibrillator or after removal of an implantable device due to infection or other reasons, as well as AutoPulse, an automated cardiopulmonary resuscitation (CPR) device for the temporary circulation of blood.

 

 

No. of Employees :

1,908

 

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

Status :

Satisfactory

 

 

Payment Behaviour :

No Complaints

 

 

Litigation :

Exist

 

 

NOTES:

Any query related to this report can be made on e-mail: infodept@mirainform.com while quoting report number, name and date.

 

 

ECGC Country Risk Classification List – December 31, 2014

 

Country Name

Previous Rating

(30.09.2014)

Current Rating

(31.12.2014)

United States

A1

A1

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

 

 

 


 

UNITED STATES - ECONOMIC OVERVIEW

 

The US has the largest and most technologically powerful economy in the world, with a per capita GDP of $49,800. In this market-oriented economy, private individuals and business firms make most of the decisions, and the federal and state governments buy needed goods and services predominantly in the private marketplace. US business firms enjoy greater flexibility than their counterparts in Western Europe and Japan in decisions to expand capital plant, to lay off surplus workers, and to develop new products. At the same time, they face higher barriers to enter their rivals' home markets than foreign firms face entering US markets. US firms are at or near the forefront in technological advances, especially in computers and in medical, aerospace, and military equipment; their advantage has narrowed since the end of World War II. The onrush of technology largely explains the gradual development of a "two-tier labor market" in which those at the bottom lack the education and the professional/technical skills of those at the top and, more and more, fail to get comparable pay raises, health insurance coverage, and other benefits. Since 1975, practically all the gains in household income have gone to the top 20% of households. Since 1996, dividends and capital gains have grown faster than wages or any other category of after-tax income. Imported oil accounts for nearly 55% of US consumption. Crude oil prices doubled between 2001 and 2006, the year home prices peaked; higher gasoline prices ate into consumers' budgets and many individuals fell behind in their mortgage payments. Oil prices climbed another 50% between 2006 and 2008, and bank foreclosures more than doubled in the same period. Besides dampening the housing market, soaring oil prices caused a drop in the value of the dollar and a deterioration in the US merchandise trade deficit, which peaked at $840 billion in 2008. The sub-prime mortgage crisis, falling home prices, investment bank failures, tight credit, and the global economic downturn pushed the United States into a recession by mid-2008. GDP contracted until the third quarter of 2009, making this the deepest and longest downturn since the Great Depression. To help stabilize financial markets, in October 2008 the US Congress established a $700 billion Troubled Asset Relief Program (TARP). The government used some of these funds to purchase equity in US banks and industrial corporations, much of which had been returned to the government by early 2011. In January 2009 the US Congress passed and President Barack OBAMA signed a bill providing an additional $787 billion fiscal stimulus to be used over 10 years - two-thirds on additional spending and one-third on tax cuts - to create jobs and to help the economy recover. In 2010 and 2011, the federal budget deficit reached nearly 9% of GDP. In 2012 the federal government reduced the growth of spending and the deficit shrank to 7.6% of GDP. Wars in Iraq and Afghanistan required major shifts in national resources from civilian to military purposes and contributed to the growth of the budget deficit and public debt. Through 2011, the direct costs of the wars totaled nearly $900 billion, according to US government figures. US revenues from taxes and other sources are lower, as a percentage of GDP, than those of most other countries. In March 2010, President OBAMA signed into law the Patient Protection and Affordable Care Act, a health insurance reform that was designed to extend coverage to an additional 32 million American citizens by 2016, through private health insurance for the general population and Medicaid for the impoverished. Total spending on health care - public plus private - rose from 9.0% of GDP in 1980 to 17.9% in 2010. In July 2010, the president signed the DODD-FRANK Wall Street Reform and Consumer Protection Act, a law designed to promote financial stability by protecting consumers from financial abuses, ending taxpayer bailouts of financial firms, dealing with troubled banks that are "too big to fail," and improving accountability and transparency in the financial system - in particular, by requiring certain financial derivatives to be traded in markets that are subject to government regulation and oversight. In December 2012, the Federal Reserve Board (Fed) announced plans to purchase $85 billion per month of mortgage-backed and Treasury securities in an effort to hold down long-term interest rates, and to keep short term rates near zero until unemployment drops below 6.5% or inflation rises above 2.5%. In late 2013, the Fed announced that it would begin scaling back long-term bond purchases to $75 billion per month in January 2014 and reduce them further as conditions warranted; the Fed, however, would keep short-term rates near zero so long as unemployment and inflation had not crossed the previously stated thresholds. Long-term problems include stagnation of wages for lower-income families, inadequate investment in deteriorating infrastructure, rapidly rising medical and pension costs of an aging population, energy shortages, and sizable current account and budget deficits.

Source : CIA


Company name and address

 

Company name:            ZOLL MEDICAL CORPORATION

 

Address:                       269 Mill Road, Chelmsford, MA 01824 - USA

 

Telephone:                    +1 978-421-9655

 

Fax:                              +1 978-421-0025

 

Website:                       www.zoll.com

 

Corporate ID#:              042711626

 

State:                           Massachusetts

 

 

Judicial form:                Corporation – Profit  

 

Date incorporated:        September 4, 1980

 

Stock:                          100 shares common (no share issued)

 

Value:                           USD 0.01= par value

 

Name of manager:         Richard A. PACKER

 

 

ACTIVITIES and OPERATIONS

 

IST

 

Business:

 

ZOLL Medical Corporation develops, manufactures, and markets resuscitation devices, related data management and software solutions, and temperature management technology worldwide.

 

The company provides technologies that help clinicians, EMS and fire professionals, and lay rescuers in treating victims needing resuscitation and critical care. It offers lifevest wearable defibrillators for various indications comprising heart attack, before or after bypass surgery, or stent placement; patients with cardiomyopathy or congestive heart failures; and patients awaiting an implantable defibrillator or after removal of an implantable device due to infection or other reasons, as well as AutoPulse, an automated cardiopulmonary resuscitation (CPR) device for the temporary circulation of blood.

 

The company also provides professional defibrillators to treat patients with sudden cardiac arrest (SCA); automated external defibrillators that analyze the heart’s rhythm and allow a rescuer to deliver an electric shock to a victim of SCA; and disposable defibrillator electrodes to monitor and deliver electrical therapy to patients, as well as provide CPR feedback.

In addition, it offers intravascular temperature management technology related to therapeutic hypothermia and rewarming; Power Infuser for the delivery of intravenous fluids; ZOLL RescueNet, a suite of data management solutions to maximize specific business processes; and CodeNet for data collection during resuscitation and organizing data into useful information related to performance measures for resuscitation practices.

 

The company markets its products directly to hospitals and EMS organizations, as well through distributors, manufacturer’s representatives, and other indirect channels in the public safety market.

 

ZOLL Medical Corporation was founded in 1980 and is headquartered in Chelmsford, Massachusetts.

As of April 25, 2012, ZOLL Medical Corporation operates as a subsidiary of Asahi Kasei Corporation.

 

 

Last news:

 

On September 26, 2014, ZOLL Medical Corporation was awarded a USD 39,848,375 federal contract by the Defense Logistics Agency Troop Support, Philadelphia, for access to airworthy defibrillators inventory for the U.S. Army, U.S. Navy, U.S. Air Force, U.S. Marine Corps and federal civilian agencies.

 

On March 9, 2015, ZOLL®Medical Corporation announced that the company’s ResQCPR System has been granted premarket approval (PMA) by the U.S. Food and Drug Administration (FDA) to market and begin U.S. distribution of the CPR adjunct system. The technology, which has been shown to improve the likelihood of survival in adult patients with non-traumatic cardiac arrest, is expected to be commercially available in mid-2015. A pivotal study evaluating the ResQCPR System, known as the ResQTRIAL, which the FDA considered in its approval process, demonstrated a 49% increase in survival to one year in adult patients who experienced out-of-hospital cardiac arrest of presumed cardiac etiology, as compared to treatment with conventional manual CPR. If widely implemented, the ResQCPR System could save thousands of lives each year in the U.S. from out-of-hospital cardiac arrest alone, based on these study results. The ResQCPR System uses Intrathoracic Pressure Regulation (IPR), a proprietary, non-invasive therapy developed by Advanced Circulatory Systems Inc. of Roseville, Minn., which ZOLL acquired in January 2015. This innovative technology uses the body’s own mechanisms to enhance circulation without the

use of pharmaceutical or other agents. The ResQCPR System is comprised of the ResQPOD® Impedance Threshold Device and the ResQPUMP® Active Compression- Decompression CPR Device, which work synergistically to improve perfusion.

 

 

 Office of the Foreign Assets Control (OFAC):

 

The company is not listed on the OFAC list.

The Specially Designated Nationals (SDN) List is a publication of OFAC which lists individuals and organizations with whom United States citizens and permanent residents are prohibited from doing business.

 

EIN:                  04-2711626

 

Staff:    1,908

 

 

Operations & branches:

 

At the headquarters, we find a factory, warehouse and office, owned.

 

 

SHAREHOLDERS & MANAGERS

 

Shareholders:

 

The Company was previously listed with the Nasdaq and delisted on May 7, 2012.

 

Shareholders include:

 

- Asahi Kasei Corporation (major shareholder)

  1 - 105 Kanda Jinbocho, Chiyoda-ku, Tokyo, 101-8101, Japan

- Vanguard Group Inc

- Waddell & Reed Investment Management Company

- Ivy Investment Management Company

- Capital Research Global Investors and others.

 

 

Management:

 

Richard A. PACKER is Executive Director and CEO.

Mr. Packer served as the President of ZOLL Medical Corp., from May 1996 to June 2008 and served as its Chief Operating Officer from 1996 to November 1999. From 1992 to 1996, he served as Chief Financial Officer and Vice President of Operations of Zoll Medical Corporation and served as its Executive Chairman from November 1999 to November 2010. From 1987 to 1992, Mr. Packer served as the Vice President of various functions for Whistler Corporation. Before joining Whistler in 1987, he served as a manager with the consulting firm of PRTM/KPMG, specializing in operations of high technology companies. Mr. Packer was Chairperson of MassMEDIC, the industry council for Medical Devices in Massachusetts. He serves as a Director of Lifecor, Inc. He has been a Director of Bruker Corporation (Formerly Bruker BioSciences Corp.) since May 16, 2007. He has been an Executive Director of ZOLL Medical Corp. since 1996. Mr. Packer serves as a member of the Compensation Committee of Lifecor, Inc. He serves on the Steering Committee for the Massachusetts Life Sciences Initiative, and is a board member of the Massachusetts Medical Device Development Center, a University of Massachusetts initiative to incubate medical device companies. Mr. Packer holds a B.S. and M. Eng. degrees from the Rensselaer Polytechnic Institute and an MBA from the Harvard Graduate School of Business Administration.

 

Jonathan A. RENNERT, President

He serves as President of ZOLL Core Products at ZOLL Medical Corporation.

Mr. Rennert served as President of ZOLL Medical Corp. since June 2008 and is primarily responsible for managing it's core defibrillator/resuscitation business. Mr. Rennert served as Chief Executive Officer and President of BioProcessors Corp. since January 21, 2007. He served as Vice President and General Manager, Analytical Sciences of PerkinElmer, Inc. He helped build and expand market-leading positions for PerkinElmer in spectroscopy, chromatography, thermal analysis and informatics. Prior to PerkinElmer, he held numerous leadership positions in operations and engineering at United Technologies' Carrier Corporation and at General Electric.

Mr. Rennert holds Master's degrees in Mechanical Engineering and Management from the Massachusetts Institute of Technology, and a Bachelor's degree in Mechanical & Aerospace Engineering from Princeton University.

 

John BERGERON, Vice President.

Takashi MUKUNO is a Director.

Partnership and subsidiaries:

 

Bio-Detek, Incorporated, incorporated in Massachusetts.

ZOLL Medical (U.K.) Ltd, incorporated in United Kingdom.

ZOLL Medical Deutschland (GmbH), incorporated in Germany.

ZOLL Medical Canada, Inc., incorporated in Canada.

ZOLL Data Systems, Inc., incorporated in Delaware.

ZOLL Medical France SNC, established in France.

ZOLL Medical Australia, Pty. Limited, incorporated in Australia.

ZOLL International Holding BV, incorporated in the Netherlands.

ZOLL Medical New Zealand Pty. Limited, incorporated in New Zealand.

ZOLL Circulation, Inc., incorporated in Delaware.

ZOLL Medical Österreich, GmbH, incorporated in Austria.

ZOLL Securities Corporation, incorporated in Massachusetts.

ZOLL Lifecor Corporation, incorporated in Delaware.

ZOLL LC International GmbH, incorporated in Germany.

 

 

FINANCIALS

 

In United States, privately held corporations are not required to publish any financials.

 

On a direct call, a financial assistant controlled the present report.

 

Sales declared for year 2013 is in excess of USD 600,000,000+ with a net profit of USD 40,000,000=

No financials available at this time for year 2014.

 

Banks:  Bank of America

                        US Bank

 

 

LEGAL FILINGS

 

Legal filings & complaints:

 

State:                           Delaware

Case number:                1:12-cv-01778-LPS

Plaintiff:                        ZOLL Medical Corporation

Defendant:                    Respironics Inc.Leonard P. Stark, presiding

Date filed:                     12/27/2012

Date of last filing:         03/17/2015

Cause:                          Patent infringement

 

State:                           Massachusetts

Case number:                1:10-cv-11041-NMG

Plaintiff:                        Koninklijke Philips Electronics N.V. et al

Defendant:                    Zoll Medical Corporation

Nathaniel                       M. Gorton, presiding

Leo T. Sorokin, referral

Date filed:                     06/18/2010

Date of last filing:         01/12/2015

Cause:                          Patent infringement

 

State:                           Texas

Case number:                7:15-cv-00063-O

Plaintiff:                        AutoMedx Inc.

Defendant:                    ZOLL Medical Corp. et al

Reed C O'Connor, presiding

Date filed:                     04/03/2015

Date of last filing:         04/24/2015

 

Secured debts summary (UCC):   numerous UCC files listed in Massachusetts

 

 

COMPANY CREDIT HISTORY

 

Trade references:

 

Date reported:               March 2015

High credit:                   USD 25,000

Now owing:                   0

Past due:                      0

Last purchase:              February 2015

Line of business:           Office supply

Paying status:               8 days beyond terms

 

Date reported:               March 2015

High credit:                   USD 1,800,000

Now owing:                   0

Past due:                      0

Last purchase:              February 2015

Line of business:           Payroll

Paying status:               As agreed

 

Date reported:               March 2015

High credit:                   USD 1,200

Now owing:                   0

Past due:                      0

Last purchase:              February 2015

Line of business:           Telecommunications

Paying status:               8 days beyond terms

 

 

Domestic credit history:

 

Domestic credit history appears as follow:

 

Monthly Payment Trends - Recent Activity

 

 

 

Date

Balance

Current

Up to 30 DBT

31-60 DBT

61-90 DBT

>90 DBT

11/14

$1,081,700

83%

4%

3%

10%

0%

12/14

$1,140,500

75%

24%

1%

0%

0%

01/15

$814,900

85%

9%

6%

0%

0%

02/15

$1,148,600

88%

11%

1%

0%

0%

03/15

$1,222,600

74%

23%

3%

0%

0%

04/15

$895,900

85%

12%

3%

0%

0%

 

National Credit Bureaus gave a medium credit risk.

 

According to our credit analysts, during the last 6 months, domestic payments were made with an average of 5 to 10 days beyond terms.

 

 

International credit history:

 

Payments of imports are currently made with an average of 2 to 5 days beyond terms.

 

 

Other comments:

 

The Company maintains a strong business.

 

The Company is in good standing.

This means that all local and federal taxes were paid on due date.

Last report was filed on 05-22-2014.

 

The risk is medium/low.

 

 

Our opinion:

 

A business connection may be conducted bur we suggest you to check regularly the terms of payments.

 

 

 


 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.63.40

UK Pound

1

Rs.95.42

Euro

1

Rs.68.49

 

INFORMATION DETAILS

 

Analysis Done by :

RAS

 

 

Report Prepared by :

VNT

 

               

RATING EXPLANATIONS

 

RATING

STATUS

PROPOSED CREDIT LINE

 

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

 

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

 

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

 

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

 

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

 

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

 

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

Credit not recommended

 

--

NB

New Business

--

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                  Payment record (10%)

Credit history (10%)                   Market trend (10%)                                Operational size (10%)

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.